Friday, October 14, 2022 2:09:50 PM
Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA
https://www.reddit.com/r/RVVTF/comments/y406v1/news_out_revive_therapeutics_announces/?utm_source=share&utm_medium=android_app&utm_name=androidcss&utm_term=1&utm_content=share_button
Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA
— Revive Therapeutics (CSE: RVV, US: RVVTF) Official (@Revive_RVV) October 14, 2022
Learn more: https://t.co/WB9m13oR6B $RVV $RVVTF #Bucillamine #Infectiousdiseases #Covid19 #FDA pic.twitter.com/GWCf7sx9S6
https://www.reddit.com/r/RVVTF/comments/y406v1/news_out_revive_therapeutics_announces/?utm_source=share&utm_medium=android_app&utm_name=androidcss&utm_term=1&utm_content=share_button
Recent RVVTF News
- Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures • ACCESS Newswire • 05/20/2026 11:45:00 AM
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
